Department of Interventional Radiology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
J Vasc Access. 2024 Jul;25(4):1129-1133. doi: 10.1177/11297298231151459. Epub 2023 Jan 27.
Our objective was to evaluate the feasibility of XperCT combined fluoroscopy to guide sharp recanalization for the treatment of chronic thoracic venous occlusive disease in hemodialysis patients.
The records of hemodialysis patients with chronic thoracic venous occlusive disease who received endovascular sharp recanalization after conventional techniques failed were retrospectively reviewed. The sharp devices used for recanalization included the stiff end of a guidewire, Chiba biopsy needle, RUPS-100 set, and transseptal needle. The needle was advanced toward a target placed at the opposite end of the occlusion and was guided by fluoroscopy and/or XperCT. While the guidewire crossed the occlusion, endovascular procedures such as percutaneous angioplasty were performed for the treatment of the occlusion.
The analysis included 32 sharp thoracic vein recanalization procedures in 29 patients. Two attempts in one patient failed, and in one patient the first attempt failed but the second attempt was successful. In one patient, two separate successful procedures were performed, and the other 26 procedures in 26 patients were successful. The overall technical success rate of sharp recanalization was 90%. The mean number of puncture attempts in the combined group was less than that of the fluoroscopy-guided alone group (2 vs 5, < 0.05). The success rate of sharp recanalization in the combined group was higher (100% vs 86%), and the recanalization time (28.5 min vs 36 min, > 0.05) was no different. There was no statistical difference in procedure-related complications between the groups.
XperCT can facilitate sharp recanalization for the treatment of chronic thoracic venous occlusive disease in hemodialysis patients.
本研究旨在评估 XperCT 联合透视引导下锐性再通术治疗血液透析患者慢性胸静脉阻塞性疾病的可行性。
回顾性分析常规技术失败后接受血管内锐性再通治疗的血液透析患者慢性胸静脉阻塞性疾病的病历资料。再通时使用的锐性器械包括导丝硬头、Chiba 活检针、RUPS-100 套件和经房间隔穿刺针。将针朝向阻塞的对侧目标推进,并通过透视和/或 XperCT 进行引导。当导丝穿过阻塞时,对阻塞进行经皮血管成形术等血管内治疗。
分析包括 29 例患者的 32 次锐性胸静脉再通术。1 例患者 2 次尝试均失败,1 例患者首次尝试失败但第 2 次成功。1 例患者进行了 2 次单独的成功手术,26 例患者中的 26 次手术均成功。锐性再通的总技术成功率为 90%。联合组的穿刺尝试次数少于单纯透视引导组(2 次比 5 次,<0.05)。联合组的锐性再通成功率更高(100%比 86%,>0.05),再通时间(28.5 分钟比 36 分钟,>0.05)无差异。两组间与操作相关的并发症发生率无统计学差异。
XperCT 可有助于血液透析患者慢性胸静脉阻塞性疾病的锐性再通治疗。